To overcome some of the limitations, researchers are employing more sophisticated models such as 3D cell cultures and organ-on-a-chip technologies. These models better mimic the tumor microenvironment and provide more accurate data on how compounds affect cancer cells in a more physiologically relevant context. Additionally, combining in vitro screening with genomic and proteomic analyses can offer deeper insights into the mechanisms of action and potential biomarkers for response.
